Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Abstract 2153: Cyclin E1 protein overexpression sensitizes ovarian cancer cells to ZN-c3, a novel, selective and oral bioavailable inhibitor of Wee1

Jianhui Ma, Wen Liu, Heekyung Chung, Hooman Izadi, Petrus DeJong, Olivier Harismendy, Jia li, Fernando Doñate, Ahmed Samatar, Mark Lackner, Laure Escoubet, Kevin Bunker, Daehwan Kim, Nathan Jameson, Tugba Yildiran Ozmen, Kangjin Jeong, Dong Zhang, Wen-An Pan, Gordon Mills

Cancer Res (2023) 83 (7_Supplement): 2153.

https://doi.org/10.1158/1538-7445.AM2023-2153

Published: 04 April 2023

View articletitled, Abstract 2153: Cyclin E1 protein overexpression sensitizes ovarian cancer cells to ZN-c3, a novel, selective and oral bioavailable inhibitor of Wee1

Journal Articles

Abstract 2605: BH3 mimetics synergize with the Wee1 inhibitor ZN-c3 by activating caspases which induce DNA damage and degrade key proteins

Hooman Izadi, Noah Ibrahim, Tiffany Hoang, Jianhui Ma, Petrus R. de Jong, Joseph Pinchman, Kevin D. Bunker, Ahmed A. Samatar, Fernando Doñate

Cancer Res (2022) 82 (12_Supplement): 2605.

https://doi.org/10.1158/1538-7445.AM2022-2605

Published: 15 June 2022

View articletitled, Abstract 2605: BH3 mimetics synergize with the Wee1 inhibitor ZN-c3 by activating caspases which induce DNA damage and degrade key proteins

Journal Articles

Abstract 2606: ZN-c3, a potent and selective Wee-1 inhibitor demonstrates anti-tumor activities in combination with other targeted therapies and overcomes PARP inhibitor resistance

Jiali Li, Jianhui Ma, Petrus R. de Jong, Hooman Izadi, Tiffany Hoang, Noah Ibrahim, Brant Boren, Sayee Hegde Hegde, Fernando Doñate, Ahmed A. Samatar

Cancer Res (2022) 82 (12_Supplement): 2606.

https://doi.org/10.1158/1538-7445.AM2022-2606

Published: 15 June 2022

View articletitled, Abstract 2606: ZN-c3, a potent and selective Wee-1 inhibitor demonstrates anti-tumor activities in combination with other targeted therapies and overcomes PARP inhibitor resistance

Journal Articles

Abstract 2591: Combination of the BCL-2 inhibitor ZN-d5 with the WEE1 inhibitor ZN-c3 shows additive or synergistic anti-tumor activity in acute myeloid leukemia (AML) models

Hooman Izadi, Tiffany Hoang, Noah Ibrahim, Joseph Pinchman, Brant C. Boren, Jianhui Ma, Petrus R. de Jong, Jiali Li, Kevin D. Bunker, Ahmed A. Samatar, Fernando Doñate

Cancer Res (2022) 82 (12_Supplement): 2591.

https://doi.org/10.1158/1538-7445.AM2022-2591

Published: 15 June 2022

View articletitled, Abstract 2591: Combination of the BCL-2 inhibitor ZN-d5 with the WEE1 inhibitor ZN-c3 shows additive or synergistic anti-tumor activity in acute myeloid leukemia (AML) models

Journal Articles

Abstract 2423: Discovery of ZN-e4, an irreversible EGFR-TKI with potent anti-tumor activity in EGFR mutant non-small-cell lung cancer

Jiali Li, Sunny Abraham, Jianhui Ma, Peter Q. Huang, Kevin D. Bunker, Fernando Doñate, Ahmed A. Samatar

Cancer Res (2021) 81 (13_Supplement): 2423.

https://doi.org/10.1158/1538-7445.AM2021-2423

Published: 01 July 2021

View articletitled, Abstract 2423: Discovery of ZN-e4, an irreversible EGFR-TKI with potent anti-tumor activity in EGFR mutant non-small-cell lung cancer

Journal Articles

Abstract 1965: Discovery of ZN-c3, a potent Wee-1 inhibitor with a differentiated pharmacologic and kinase selectivity profile

Jiali Li, Brant Boren, Peter Q. Huang, Kevin D. Bunker, Fernando Doñate, Ahmed A. Samatar

Cancer Res (2021) 81 (13_Supplement): 1965.

https://doi.org/10.1158/1538-7445.AM2021-1965

Published: 01 July 2021

View articletitled, Abstract 1965: Discovery of ZN-c3, a potent Wee-1 inhibitor with a differentiated pharmacologic and kinase selectivity profile

Journal Articles

Abstract 4373: Discovery of ZN-c5, a novel potent and oral selective estrogen receptor degrader

Ahmed A. Samatar, Jiali Li, Sayee Hegde, Peter Huang, Jianhui Ma, Kevin Bunker, Robert Winkler, Fernando Donate, Masha Sergeeva

Cancer Res (2020) 80 (16_Supplement): 4373.

https://doi.org/10.1158/1538-7445.AM2020-4373

Published: 15 August 2020

View articletitled, Abstract 4373: Discovery of ZN-c5, a novel potent and oral selective estrogen receptor degrader

Journal Articles

Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody–Drug Conjugates

Cancer Res (2018) 78 (8): 2115–2126.

https://doi.org/10.1158/0008-5472.CAN-17-3202

Published: 12 April 2018

View articletitled, Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody–Drug Conjugates

Includes: Supplementary data

Journal Articles

Abstract 2709: Evaluation of CD37 expression and binding of AGS67E, an antibody-drug conjugate (ADC) against CD37, on white blood cells (WBCs) collected from phase I non-Hodgkin lymphoma (NHL) patients

Sher Karki, Hector Avina, Jacqueline Lackey, Ahmed Sawas, Kerry J. Savage, Raymond Perez, Ranjana Advani, Jasmine Zain, Owen A. O'Connor, Sara Gulesserian, Hui Zhao, Peng Yang, Karen Morrison, Leonard Reyno, Fernando Donate

Cancer Res (2017) 77 (13_Supplement): 2709.

https://doi.org/10.1158/1538-7445.AM2017-2709

Published: 01 July 2017

View articletitled, Abstract 2709: Evaluation of CD37 expression and binding of AGS67E, an antibody-drug conjugate (ADC) against CD37, on white blood cells (WBCs) collected from phase I non-Hodgkin lymphoma (NHL) patients

Journal Articles

Abstract 574: AGS62P1, a novel site-specific antibody drug conjugate targeting FLT3 exhibits potent anti-tumor activity regardless of FLT3 kinase activation status

Cancer Res (2016) 76 (14_Supplement): 574.

https://doi.org/10.1158/1538-7445.AM2016-574

Published: 15 July 2016

View articletitled, Abstract 574: AGS62P1, a novel site-specific antibody drug conjugate targeting FLT3 exhibits potent anti-tumor activity regardless of FLT3 kinase activation status

Journal Articles

Abstract 3853: Potential mechanisms for thrombocytopenia and neutropenia induced by antibody-drug conjugates

Hui Zhao, Sara Gulesserian, Sathish K. Ganesan, Zhilan Zeng, Jimmy Ou, Veronica Robles, Josh Snyder, David R. Stover, Fernando Donate

Cancer Res (2016) 76 (14_Supplement): 3853.

https://doi.org/10.1158/1538-7445.AM2016-3853

Published: 15 July 2016

View articletitled, Abstract 3853: Potential mechanisms for thrombocytopenia and neutropenia induced by antibody-drug conjugates

Journal Articles

Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

Cancer Res (2016) 76 (10): 3003–3013.

https://doi.org/10.1158/0008-5472.CAN-15-1313

Published: 12 May 2016

View articletitled, Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

Includes: Supplementary data

Journal Articles

Abstract 2650: Ags67e, an anti-cd37 monomethyl auristatin e antibody (mmae) drug conjugate as a potential therapeutic for non-hodgkin's lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia

Cancer Res (2014) 74 (19_Supplement): 2650.

https://doi.org/10.1158/1538-7445.AM2014-2650

Published: 01 October 2014

View articletitled, Abstract 2650: Ags67e, an anti-cd37 monomethyl auristatin e antibody (mmae) drug conjugate as a potential therapeutic for non-hodgkin's lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia

Journal Articles

Abstract 1274: SLITRK6, the target of a novel antibody drug conjugate AGS15E, is expressed in bladder and other cancers.

Peng YANG, Jeffrey Coleman, Ying Li, Yi Zhang, Candice Junge, Kendall Morrison, Fernando Donate, David Stover, Karen Morrison

Cancer Res (2013) 73 (8_Supplement): 1274.

https://doi.org/10.1158/1538-7445.AM2013-1274

Published: 15 April 2013

View articletitled, Abstract 1274: SLITRK6, the target of a novel antibody drug conjugate AGS15E, is expressed in bladder and other cancers.

Journal Articles

The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3

Christopher P. Guise, Maria R. Abbattista, Rachelle S. Singleton, Samuel D. Holford, Joanna Connolly, Gabi U. Dachs, Stephen B. Fox, Robert Pollock, Justin Harvey, Parry Guilford, Fernando Doñate, William R. Wilson, Adam V. Patterson

Cancer Res (2010) 70 (4): 1573–1584.

https://doi.org/10.1158/0008-5472.CAN-09-3237

Published: 14 February 2010

View articletitled, The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3

Includes: Supplementary data

Journal Articles

Enhanced anti-melanoma activity via manipulation of reactive oxygen species

John Fruehauf, Valerie Trapp, Fernando Donate, Andrew Mazar, Frank Meyskens

Cancer Res (2007) 67 (9_Supplement): 2414.

Published: 01 May 2007

View articletitled, Enhanced anti-melanoma activity via manipulation of reactive oxygen species

Journal Articles

ATN-224, an orally available small molecule inhibitor of SOD1, inhibits multiple signaling pathways associated with myeloma progression and has antitumor activity in a murine model of refractory myeloma growth

Richard A. Campbell, Melinda S. Gordon, Oscar Betancourt, Jose Juarez, Fernando Donate, Andrew Mazar, James R. Berenson

Cancer Res (2006) 66 (8_Supplement): 1141.

Published: 15 April 2006

View articletitled, ATN-224, an orally available small molecule inhibitor of SOD1, inhibits multiple signaling pathways associated with myeloma progression and has antitumor activity in a murine model of refractory myeloma growth

Journal Articles

The inhibition of CuZn superoxide dismutase (SOD1) by ATN-224, a second generation tetrathiomolybdate, interferes with multiple signaling pathways in tumor and endothelial cells in vitro

Jose C. Juarez, Mari M. Manuia, Oscar Betancourt, Jr., Andrew P. Mazar, Fernando Donate

Cancer Res (2006) 66 (8_Supplement): 1101.

Published: 15 April 2006

View articletitled, The inhibition of CuZn superoxide dismutase (SOD1) by ATN-224, a second generation tetrathiomolybdate, interferes with multiple signaling pathways in tumor and endothelial cells in vitro

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 2153: Cyclin E1 protein overexpression sensitizes ovarian cancer cells to ZN-c3, a novel, selective and oral bioavailable inhibitor of Wee1

Abstract 2605: BH3 mimetics synergize with the Wee1 inhibitor ZN-c3 by activating caspases which induce DNA damage and degrade key proteins

Abstract 2606: ZN-c3, a potent and selective Wee-1 inhibitor demonstrates anti-tumor activities in combination with other targeted therapies and overcomes PARP inhibitor resistance

Abstract 2591: Combination of the BCL-2 inhibitor ZN-d5 with the WEE1 inhibitor ZN-c3 shows additive or synergistic anti-tumor activity in acute myeloid leukemia (AML) models

Abstract 2423: Discovery of ZN-e4, an irreversible EGFR-TKI with potent anti-tumor activity in EGFR mutant non-small-cell lung cancer

Abstract 1965: Discovery of ZN-c3, a potent Wee-1 inhibitor with a differentiated pharmacologic and kinase selectivity profile

Abstract 4373: Discovery of ZN-c5, a novel potent and oral selective estrogen receptor degrader

Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody–Drug Conjugates

Abstract 2709: Evaluation of CD37 expression and binding of AGS67E, an antibody-drug conjugate (ADC) against CD37, on white blood cells (WBCs) collected from phase I non-Hodgkin lymphoma (NHL) patients

Abstract 574: AGS62P1, a novel site-specific antibody drug conjugate targeting FLT3 exhibits potent anti-tumor activity regardless of FLT3 kinase activation status

Abstract 3853: Potential mechanisms for thrombocytopenia and neutropenia induced by antibody-drug conjugates

Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

Abstract 2650: Ags67e, an anti-cd37 monomethyl auristatin e antibody (mmae) drug conjugate as a potential therapeutic for non-hodgkin's lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia

Abstract 1274: SLITRK6, the target of a novel antibody drug conjugate AGS15E, is expressed in bladder and other cancers.

The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3

Enhanced anti-melanoma activity via manipulation of reactive oxygen species

ATN-224, an orally available small molecule inhibitor of SOD1, inhibits multiple signaling pathways associated with myeloma progression and has antitumor activity in a murine model of refractory myeloma growth

The inhibition of CuZn superoxide dismutase (SOD1) by ATN-224, a second generation tetrathiomolybdate, interferes with multiple signaling pathways in tumor and endothelial cells in vitro

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only